of Eli Liy. Take a map. Take a look.Up over 3%. The U pharmaceutical giant releasing more data on its obesity pill. Patients with obesity and diabetes lost about 10 and a half% of their body weight.The new data clears the way for Lily to seek regulatory approval. Guggenheim analyst Sheamus Fernandez joins us now. He's got a buy rating on Lily.Price target of 875. So, how do you take this news. You know, we got the previous data.there seemed to be some disappointment perhaps at the average weight loss. Has t ...